Companies / Diasome Pharmaceuticals
Diasome Pharmaceuticals
Company
Diasome Pharmaceuticals develops therapies for metabolic diseases, particularly diabetes, by targeting the liver with its Hepatocyte-Directed Vesicle platform.
Diasome Pharmaceuticals has 1 investor on file, among them T1D Fund. Its site was last checked 6 Nov 2026: site answers.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
More from T1D Fund
29 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Diasome Pharmaceuticals and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when T1D Fund adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/diasome.com/investors
# also
GET /v1/companies/diasome.com
GET /v1/companies/diasome.com/news